{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:27:19Z","timestamp":1791358039201,"version":"4.3.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002203","name":"Brain Tumour Charity","doi-asserted-by":"publisher","award":["GN-000380"],"award-info":[{"award-number":["GN-000380"]}],"id":[{"id":"10.13039\/501100002203","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["875510"],"award-info":[{"award-number":["875510"]}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["106169\/ZZ14\/Z"],"award-info":[{"award-number":["106169\/ZZ14\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>H3K27-altered Diffuse Midline Glioma (DMG) is a universally fatal paediatric brainstem tumour. The prevalent driver mutation H3K27M creates a unique epigenetic landscape that may also establish therapeutic vulnerabilities to epigenetic inhibitors. However, while HDAC, EZH2 and BET inhibitors have proven somewhat effective in pre-clinical models, none have translated into clinical benefit due to either poor blood\u2013brain barrier penetration, lack of efficacy or toxicity. Thus, there remains an urgent need for new DMG treatments. Here, we performed wider screening of an epigenetic inhibitor library and identified inhibitors of protein arginine methyltransferases (PRMTs) among the top hits reducing DMG cell viability. Two of the most effective inhibitors, LLY-283 and GSK591, were targeted against PRMT5 using distinct binding mechanisms and reduced the viability of a subset of DMG cells expressing wild-type <jats:italic>TP53<\/jats:italic> and mutant <jats:italic>ACVR1<\/jats:italic>. RNA-sequencing and phenotypic analyses revealed that LLY-283 could reduce the viability, clonogenicity and invasion of DMG cells in vitro, representing three clinically important phenotypes, but failed to prolong survival in an orthotopic xenograft model. Together, these data show the challenges of DMG treatment and highlight PRMT5 inhibitors for consideration in future studies of combination treatments.<\/jats:p>","DOI":"10.1038\/s41598-023-48652-x","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T11:02:21Z","timestamp":1704279741000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo"],"prefix":"10.1038","volume":"14","author":[{"given":"Elizabeth J.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leire","family":"Balaguer-Lluna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Cribbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Philpott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Browne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Fu","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Oppermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel M.","family":"Carcaboso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex N.","family":"Bullock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Farnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"issue":"12","key":"48652_CR1","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1038\/SJ.BJC.6603800","volume":"96","author":"K Pritchard-Jones","year":"2007","unstructured":"Pritchard-Jones, K. Childhood cancer in Britain: Incidence, survival and mortality. Br. J. Cancer 96(12), 1927. https:\/\/doi.org\/10.1038\/SJ.BJC.6603800 (2007).","journal-title":"Br. J. Cancer"},{"issue":"5","key":"48652_CR2","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1042\/BST20190315","volume":"47","author":"JF Wong","year":"2019","unstructured":"Wong, J. F., Brown, E. J., Williams, E. & Bullock, A. N. Fostering open collaboration in drug development for paediatric brain tumours. Biochem. Soc. Trans. 47(5), 1471\u20131479. https:\/\/doi.org\/10.1042\/BST20190315 (2019).","journal-title":"Biochem. Soc. Trans."},{"key":"48652_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.25259\/SNI_102_2022","volume":"13","author":"HP Prajapati","year":"2022","unstructured":"Prajapati, H. P. & Kannaujia, S. K. A simplified overview of the World Health Organization classification of central nervous system tumors 2021. Surg. Neurol. Int. 13, 252. https:\/\/doi.org\/10.25259\/SNI_102_2022 (2022).","journal-title":"Surg. Neurol. Int."},{"issue":"1","key":"48652_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/J.CTRV.2011.06.007","volume":"38","author":"MHA Jansen","year":"2012","unstructured":"Jansen, M. H. A., van Vuurden, D. G., Vandertop, W. P. & Kaspers, G. J. L. Diffuse intrinsic pontine gliomas: A systematic update on clinical trials and biology. Cancer Treat Rev. 38(1), 27\u201335. https:\/\/doi.org\/10.1016\/J.CTRV.2011.06.007 (2012).","journal-title":"Cancer Treat Rev."},{"issue":"4","key":"48652_CR5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00401-014-1307-x","volume":"128","author":"V Caretti","year":"2014","unstructured":"Caretti, V. et al. Subventricular spread of diffuse intrinsic pontine glioma. Acta Neuropathol. 128(4), 605\u2013607. https:\/\/doi.org\/10.1007\/s00401-014-1307-x (2014).","journal-title":"Acta Neuropathol."},{"key":"48652_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00092","author":"TA Kluiver","year":"2020","unstructured":"Kluiver, T. A., Alieva, M., van Vuurden, D. G., Wehrens, E. J. & Rios, A. C. Invaders exposed: Understanding and targeting tumor cell invasion in diffuse intrinsic pontine glioma. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2020.00092 (2020).","journal-title":"Front. Oncol."},{"key":"48652_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3389\/fonc.2012.00205","volume":"2","author":"KE Warren","year":"2012","unstructured":"Warren, K. E. Diffuse intrinsic pontine glioma: poised for progress. Front. Oncol. 2, 205. https:\/\/doi.org\/10.3389\/fonc.2012.00205 (2012).","journal-title":"Front. Oncol."},{"issue":"5","key":"48652_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00381-017-3352-y","volume":"33","author":"A Morales La Madrid","year":"2017","unstructured":"Morales La Madrid, A. et al. Second re-irradiation for DIPG progression, re-considering \u201cold strategies\u201d with new approaches. Child\u2019s Nerv. Syst. 33(5), 849\u2013852. https:\/\/doi.org\/10.1007\/s00381-017-3352-y (2017).","journal-title":"Child\u2019s Nerv. Syst."},{"issue":"9","key":"48652_CR9","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/NEUONC\/NOX107","volume":"19","author":"T Cooney","year":"2017","unstructured":"Cooney, T. et al. Contemporary survival endpoints: An international diffuse intrinsic pontine glioma registry study. Neuro Oncology 19(9), 1279. https:\/\/doi.org\/10.1093\/NEUONC\/NOX107 (2017).","journal-title":"Neuro Oncology"},{"key":"48652_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/S11940-019-0577-Y","author":"NA Vitanza","year":"2019","unstructured":"Vitanza, N. A. & Monje, M. \u2018Diffuse intrinsic pontine glioma: From diagnosis to next-generation clinical trials. Curr. Treat Options Neurol. https:\/\/doi.org\/10.1007\/S11940-019-0577-Y (2019).","journal-title":"Curr. Treat Options Neurol."},{"issue":"7384","key":"48652_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10833","volume":"482","author":"J Schwartzentruber","year":"2012","unstructured":"Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482(7384), 226\u2013231. https:\/\/doi.org\/10.1038\/nature10833 (2012).","journal-title":"Nature"},{"issue":"3","key":"48652_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/ng.1102","volume":"44","author":"G Wu","year":"2012","unstructured":"Wu, G. et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 44(3), 251\u2013253. https:\/\/doi.org\/10.1038\/ng.1102 (2012).","journal-title":"Nat. Genet."},{"issue":"5","key":"48652_CR13","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccr.2013.10.006","volume":"24","author":"S Bender","year":"2013","unstructured":"Bender, S. et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 24(5), 660\u2013672. https:\/\/doi.org\/10.1016\/j.ccr.2013.10.006 (2013).","journal-title":"Cancer Cell"},{"issue":"4","key":"48652_CR14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nm.4293","volume":"23","author":"F Mohammad","year":"2017","unstructured":"Mohammad, F. et al. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat. Med. 23(4), 483\u2013492. https:\/\/doi.org\/10.1038\/nm.4293 (2017).","journal-title":"Nat. Med."},{"issue":"8","key":"48652_CR15","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/s41588-021-00897-w","volume":"53","author":"GL Brien","year":"2021","unstructured":"Brien, G. L. et al. Simultaneous disruption of PRC2 and enhancer function underlies histone H3.3\u2013K27M oncogenic activity in human hindbrain neural stem cells. Nat. Genet. 53(8), 1221\u20131232. https:\/\/doi.org\/10.1038\/s41588-021-00897-w (2021).","journal-title":"Nat. Genet."},{"issue":"5","key":"48652_CR16","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/ng.2938","volume":"46","author":"G Wu","year":"2014","unstructured":"Wu, G. et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat. Genet. 46(5), 444\u2013450. https:\/\/doi.org\/10.1038\/ng.2938 (2014).","journal-title":"Nat. Genet."},{"issue":"5","key":"48652_CR17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/ng.2950","volume":"46","author":"AM Fontebasso","year":"2014","unstructured":"Fontebasso, A. M. et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat. Genet. 46(5), 462\u2013466. https:\/\/doi.org\/10.1038\/ng.2950 (2014).","journal-title":"Nat. Genet."},{"issue":"5","key":"48652_CR18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/ng.2936","volume":"46","author":"P Buczkowicz","year":"2014","unstructured":"Buczkowicz, P. et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat. Genet. 46(5), 451\u2013456. https:\/\/doi.org\/10.1038\/ng.2936 (2014).","journal-title":"Nat. Genet."},{"issue":"5","key":"48652_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ng.2925","volume":"46","author":"KR Taylor","year":"2014","unstructured":"Taylor, K. R. et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat. Genet. 46(5), 457\u2013461. https:\/\/doi.org\/10.1038\/ng.2925 (2014).","journal-title":"Nat. Genet."},{"issue":"12","key":"48652_CR20","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/nm.3716","volume":"20","author":"R Hashizume","year":"2014","unstructured":"Hashizume, R. et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat. Med. 20(12), 1394\u20131396. https:\/\/doi.org\/10.1038\/nm.3716 (2014).","journal-title":"Nat. Med."},{"issue":"4","key":"48652_CR21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nm.4296","volume":"23","author":"A Piunti","year":"2017","unstructured":"Piunti, A. et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat. Med. 23(4), 493\u2013500. https:\/\/doi.org\/10.1038\/nm.4296 (2017).","journal-title":"Nat. Med."},{"issue":"6","key":"48652_CR22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nm.3855","volume":"21","author":"CS Grasso","year":"2015","unstructured":"Grasso, C. S. et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat. Med. 21(6), 555\u2013559. https:\/\/doi.org\/10.1038\/nm.3855 (2015).","journal-title":"Nat. Med."},{"key":"48652_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-017-0184-0","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. Combination of EZH2 nhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma. Cell Biosci. https:\/\/doi.org\/10.1186\/s13578-017-0184-0 (2017).","journal-title":"Cell Biosci."},{"issue":"5","key":"48652_CR24","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ccell.2019.09.005","volume":"36","author":"JN Anastas","year":"2019","unstructured":"Anastas, J. N. et al. Re-programing chromatin with a bifunctional LSD1\/HDAC inhibitor induces therapeutic differentiation in DIPG. Cancer Cell 36(5), 528-544.e10. https:\/\/doi.org\/10.1016\/j.ccell.2019.09.005 (2019).","journal-title":"Cancer Cell"},{"issue":"1","key":"48652_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","volume":"65","author":"RS Blanc","year":"2017","unstructured":"Blanc, R. S. & Richard, S. Arginine methylation: The coming of age. Mol. Cell 65(1), 8\u201324. https:\/\/doi.org\/10.1016\/j.molcel.2016.11.003 (2017).","journal-title":"Mol. Cell"},{"issue":"3","key":"48652_CR26","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/nsmb.1568","volume":"16","author":"Q Zhao","year":"2009","unstructured":"Zhao, Q. et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat Struct Mol Biol 16(3), 304\u2013311. https:\/\/doi.org\/10.1038\/nsmb.1568 (2009).","journal-title":"Nat Struct Mol Biol"},{"issue":"21","key":"48652_CR27","doi-asserted-by":"publisher","first-page":"9630","DOI":"10.1128\/MCB.24.21.9630-9645.2004","volume":"24","author":"S Pal","year":"2004","unstructured":"Pal, S., Vishwanath, S. N., Erdjument-Bromage, H., Tempst, P. & Sif, S. Human SWI\/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol. Cell. Biol. 24(21), 9630\u20139645. https:\/\/doi.org\/10.1128\/MCB.24.21.9630-9645.2004 (2004).","journal-title":"Mol. Cell. Biol."},{"issue":"2","key":"48652_CR28","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/NSMB.2209","volume":"19","author":"V Migliori","year":"2012","unstructured":"Migliori, V. et al. Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance. Nat. Struct. Mol. Biol. 19(2), 136\u2013145. https:\/\/doi.org\/10.1038\/NSMB.2209 (2012).","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"48652_CR29","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1038\/s41467-018-04863-9","volume":"9","author":"A Scaglione","year":"2018","unstructured":"Scaglione, A. et al. PRMT5-mediated regulation of developmental myelination. Nat. Commun. 9(1), 2840. https:\/\/doi.org\/10.1038\/s41467-018-04863-9 (2018).","journal-title":"Nat. Commun."},{"issue":"52","key":"48652_CR30","doi-asserted-by":"publisher","first-page":"44424","DOI":"10.1074\/jbc.M111.277046","volume":"286","author":"J Huang","year":"2011","unstructured":"Huang, J., Vogel, G., Yu, Z., Almazan, G. & Richard, S. Type II arginine methyltransferase PRMT5 regulates gene expression of inhibitors of differentiation\/DNA binding Id2 and Id4 during glial cell differentiation. J. Biol. Chem. 286(52), 44424\u201344432. https:\/\/doi.org\/10.1074\/jbc.M111.277046 (2011).","journal-title":"J. Biol. Chem."},{"issue":"1","key":"48652_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11060-014-1419-0","volume":"118","author":"X Han","year":"2014","unstructured":"Han, X. et al. Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro. J. Neurooncol. 118(1), 61\u201372. https:\/\/doi.org\/10.1007\/s11060-014-1419-0 (2014).","journal-title":"J. Neurooncol."},{"issue":"1","key":"48652_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-21204-5","volume":"12","author":"P Sachamitr","year":"2021","unstructured":"Sachamitr, P. et al. PRMT5 inhibition disrupts splicing and stemness in glioblastoma. Nat. Commun. 12(1), 1\u201317. https:\/\/doi.org\/10.1038\/s41467-021-21204-5 (2021).","journal-title":"Nat. Commun."},{"issue":"10","key":"48652_CR33","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1172\/JCI85239","volume":"126","author":"Y Jin","year":"2016","unstructured":"Jin, Y. et al. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. J. Clin. Investig. 126(10), 3961\u20133980. https:\/\/doi.org\/10.1172\/JCI85239 (2016).","journal-title":"J. Clin. Investig."},{"issue":"1","key":"48652_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169485","volume":"12","author":"T Hennika","year":"2017","unstructured":"Hennika, T. et al. Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models. PLoS One 12(1), e0169485. https:\/\/doi.org\/10.1371\/journal.pone.0169485 (2017).","journal-title":"PLoS One"},{"issue":"12","key":"48652_CR35","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s41416-020-01079-x","volume":"123","author":"MM Mita","year":"2020","unstructured":"Mita, M. M. & Mita, A. C. Bromodomain inhibitors a decade later: A promise unfulfilled?. Br. J. Cancer 123(12), 1713\u20131714. https:\/\/doi.org\/10.1038\/s41416-020-01079-x (2020).","journal-title":"Br. J. Cancer"},{"issue":"1","key":"48652_CR36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","volume":"20","author":"SR Daigle","year":"2011","unstructured":"Daigle, S. R. et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20(1), 53\u201365. https:\/\/doi.org\/10.1016\/j.ccr.2011.06.009 (2011).","journal-title":"Cancer Cell"},{"issue":"7","key":"48652_CR37","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1021\/acsmedchemlett.8b00014","volume":"9","author":"ZQ Bonday","year":"2018","unstructured":"Bonday, Z. Q. et al. LLY-283, a potent and selective inhibitor of arginine methyltransferase 5, PRMT5, with antitumor activity. ACS Med. Chem. Lett. 9(7), 612\u2013617. https:\/\/doi.org\/10.1021\/acsmedchemlett.8b00014 (2018).","journal-title":"ACS Med. Chem. Lett."},{"issue":"9","key":"48652_CR38","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1158\/1535-7163.MCT-06-0698","volume":"6","author":"AL Howes","year":"2007","unstructured":"Howes, A. L. et al. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol. Cancer Ther. 6(9), 2505\u20132514. https:\/\/doi.org\/10.1158\/1535-7163.MCT-06-0698 (2007).","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"48652_CR39","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/NEN.0000000000000216","volume":"74","author":"IC Taylor","year":"2015","unstructured":"Taylor, I. C. et al. Disrupting NOTCH slows diffuse intrinsic pontine glioma growth, enhances radiation sensitivity, and shows combinatorial efficacy with bromodomain inhibition. J. Neuropathol. Exp. Neurol. 74(8), 778\u2013790. https:\/\/doi.org\/10.1097\/NEN.0000000000000216 (2015).","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"5","key":"48652_CR40","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.ccell.2017.03.011","volume":"31","author":"S Nagaraja","year":"2017","unstructured":"Nagaraja, S. et al. Transcriptional dependencies in diffuse intrinsic pontine glioma. Cancer Cell 31(5), 635-652.e6. https:\/\/doi.org\/10.1016\/j.ccell.2017.03.011 (2017).","journal-title":"Cancer Cell"},{"key":"48652_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/FCELL.2020.00546","author":"A Perla","year":"2020","unstructured":"Perla, A. et al. Histone deacetylase inhibitors in pediatric brain cancers: Biological activities and therapeutic potential. Front. Cell Dev. Biol. https:\/\/doi.org\/10.3389\/FCELL.2020.00546 (2020).","journal-title":"Front. Cell Dev. Biol."},{"issue":"6","key":"48652_CR42","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/nchembio.1810","volume":"11","author":"E Chan-Penebre","year":"2015","unstructured":"Chan-Penebre, E. et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat. Chem. Biol. 11(6), 432\u2013437. https:\/\/doi.org\/10.1038\/nchembio.1810 (2015).","journal-title":"Nat. Chem. Biol."},{"issue":"24","key":"48652_CR43","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/S0960-9822(01)00592-9","volume":"11","author":"G Meister","year":"2001","unstructured":"Meister, G. et al. Methylation of Sm proteins by a complex containing PRMT5 and the putative U snRNP assembly factor pICln. Curr. Biol. 11(24), 1990\u20131994. https:\/\/doi.org\/10.1016\/S0960-9822(01)00592-9 (2001).","journal-title":"Curr. Biol."},{"issue":"1","key":"48652_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-019-0420-8","volume":"2","author":"DM Carvalho","year":"2019","unstructured":"Carvalho, D. M. et al. ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. Commun. Biol. 2(1), 1\u201310. https:\/\/doi.org\/10.1038\/s42003-019-0420-8 (2019).","journal-title":"Commun. Biol."},{"issue":"17","key":"48652_CR45","doi-asserted-by":"publisher","first-page":"10061","DOI":"10.1021\/acs.jmedchem.0c01199","volume":"63","author":"D Smil","year":"2020","unstructured":"Smil, D. et al. Leveraging an open science drug discovery model to develop CNS-penetrant ALK2 inhibitors for the treatment of diffuse intrinsic pontine glioma. J. Med. Chem. 63(17), 10061\u201310085. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01199 (2020).","journal-title":"J. Med. Chem."},{"issue":"9","key":"48652_CR46","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.1021\/acs.jmedchem.0c00395","volume":"63","author":"D Ensan","year":"2020","unstructured":"Ensan, D. et al. Targeting ALK2: An open science approach to developing therapeutics for the treatment of diffuse intrinsic pontine glioma. J. Med. Chem. 63(9), 4978\u20134996. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00395 (2020).","journal-title":"J. Med. Chem."},{"issue":"5","key":"48652_CR47","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1158\/0008-5472.CAN-15-1766","volume":"76","author":"L Liu","year":"2016","unstructured":"Liu, L. et al. Arginine methylation of SREBP1a via PRMT5 promotes de novo lipogenesis and tumor growth. Cancer Res. 76(5), 1260\u20131272. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1766 (2016).","journal-title":"Cancer Res."},{"issue":"14","key":"48652_CR48","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1093\/hmg\/ddx155","volume":"26","author":"J Zhao","year":"2017","unstructured":"Zhao, J. et al. APOE \u03b54\/\u03b54 diminishes neurotrophic function of human iPSC-derived astrocytes. Hum. Mol. Genet. 26(14), 2690\u20132700. https:\/\/doi.org\/10.1093\/hmg\/ddx155 (2017).","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"48652_CR49","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1471-4159.2008.05615.x","volume":"107","author":"ML Olsen","year":"2008","unstructured":"Olsen, M. L. & Sontheimer, H. Functional implications for Kir4.1 channels in glial biology: From K + buffering to cell differentiation. J. Neurochem. 107(3), 589\u2013601. https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05615.x (2008).","journal-title":"J. Neurochem."},{"issue":"47","key":"48652_CR50","doi-asserted-by":"publisher","first-page":"9343","DOI":"10.1523\/JNEUROSCI.0103-19.2019","volume":"39","author":"EG Sozmen","year":"2019","unstructured":"Sozmen, E. G. et al. White matter stroke induces a unique oligo-astrocyte niche that inhibits recovery. J. Neurosci. 39(47), 9343\u20139359. https:\/\/doi.org\/10.1523\/JNEUROSCI.0103-19.2019 (2019).","journal-title":"J. Neurosci."},{"issue":"5","key":"48652_CR51","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/aps.2010.39","volume":"31","author":"X Yao","year":"2010","unstructured":"Yao, X. et al. Promotion of self-renewal of embryonic stem cells by midkine. Acta Pharmacol. Sin. 31(5), 629\u2013637. https:\/\/doi.org\/10.1038\/aps.2010.39 (2010).","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"48652_CR52","doi-asserted-by":"publisher","first-page":"9248","DOI":"10.1038\/srep09248","volume":"5","author":"P Chen","year":"2015","unstructured":"Chen, P. et al. EphB2 activation is required for ependymoma development as well as inhibits differentiation and promotes proliferation of the transformed cell. Sci. Rep. 5(1), 9248. https:\/\/doi.org\/10.1038\/srep09248 (2015).","journal-title":"Sci. Rep."},{"issue":"12","key":"48652_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114739","volume":"9","author":"CJ Sandberg","year":"2014","unstructured":"Sandberg, C. J., Vik-Mo, E. O., Behnan, J., Helseth, E. & Langmoen, I. A. Transcriptional profiling of adult neural stem-like cells from the human brain. PLoS One 9(12), e114739. https:\/\/doi.org\/10.1371\/journal.pone.0114739 (2014).","journal-title":"PLoS One"},{"issue":"1\u20132","key":"48652_CR54","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/J.JIM.2009.06.008","volume":"347","author":"Y Hu","year":"2009","unstructured":"Hu, Y. & Smyth, G. K. ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 347(1\u20132), 70\u201378. https:\/\/doi.org\/10.1016\/J.JIM.2009.06.008 (2009).","journal-title":"J. Immunol. Methods"},{"issue":"10","key":"48652_CR55","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1101\/gad.235515.113","volume":"28","author":"K Yan","year":"2014","unstructured":"Yan, K. et al. Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy. Genes Dev. 28(10), 1085\u20131100. https:\/\/doi.org\/10.1101\/gad.235515.113 (2014).","journal-title":"Genes Dev."},{"issue":"7","key":"48652_CR56","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41573-021-00159-8","volume":"20","author":"Q Wu","year":"2021","unstructured":"Wu, Q., Schapira, M., Arrowsmith, C. H. & Barsyte-Lovejoy, D. Protein arginine methylation: From enigmatic functions to therapeutic targeting. Nat. Rev. Drug Discov. 20(7), 509\u2013530. https:\/\/doi.org\/10.1038\/s41573-021-00159-8 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"48652_CR57","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41419-020-02771-9","volume":"11","author":"W Barczak","year":"2020","unstructured":"Barczak, W. et al. PRMT5 promotes cancer cell migration and invasion through the E2F pathway. Cell Death Dis. 11(7), 572. https:\/\/doi.org\/10.1038\/s41419-020-02771-9 (2020).","journal-title":"Cell Death Dis."},{"issue":"20","key":"48652_CR58","doi-asserted-by":"publisher","first-page":"7851","DOI":"10.1158\/0008-5472.CAN-10-1223","volume":"70","author":"N Sugiyama","year":"2010","unstructured":"Sugiyama, N. et al. Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation. Cancer Res. 70(20), 7851\u20137861 (2010).","journal-title":"Cancer Res."},{"issue":"1","key":"48652_CR59","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/S11010-020-03774-Y","volume":"471","author":"M Louca","year":"2020","unstructured":"Louca, M., Zaravinos, A., Stylianopoulos, T. & Gkretsi, V. ILK silencing inhibits migration and invasion of more invasive glioblastoma cells by downregulating ROCK1 and Fascin-1. Mol. Cell. Biochem. 471(1), 6. https:\/\/doi.org\/10.1007\/S11010-020-03774-Y (2020).","journal-title":"Mol. Cell. Biochem."},{"issue":"5","key":"48652_CR60","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/J.CELLSIG.2013.01.029","volume":"25","author":"X Sun","year":"2013","unstructured":"Sun, X., Gao, X., Zhou, L., Sun, L. & Lu, C. PDGF-BB-induced MT1-MMP expression regulates proliferation and invasion of mesenchymal stem cells in 3-dimensional collagen via MEK\/ERK1\/2 and PI3K\/AKT signaling. Cell Signal 25(5), 1279\u20131287. https:\/\/doi.org\/10.1016\/J.CELLSIG.2013.01.029 (2013).","journal-title":"Cell Signal"},{"issue":"2","key":"48652_CR61","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s11060-016-2168-z","volume":"129","author":"J-N Tung","year":"2016","unstructured":"Tung, J.-N. et al. Inhibition of pentraxin 3 in glioma cells impairs proliferation and invasion in vitro and in vivo. J. Neuro-Oncol. 129(2), 201\u2013209 (2016).","journal-title":"J. Neuro-Oncol."},{"key":"48652_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.08.017","author":"A Mackay","year":"2017","unstructured":"Mackay, A. et al. Integrated molecular meta-analysis of 1000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell https:\/\/doi.org\/10.1016\/j.ccell.2017.08.017 (2017).","journal-title":"Cancer Cell"},{"issue":"4","key":"48652_CR63","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41388-021-02102-y","volume":"41","author":"IJ Findlay","year":"2022","unstructured":"Findlay, I. J. et al. Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies. Oncogene 41(4), 461\u2013475. https:\/\/doi.org\/10.1038\/s41388-021-02102-y (2022).","journal-title":"Oncogene"},{"issue":"12","key":"48652_CR64","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1038\/ncb1802","volume":"10","author":"M Jansson","year":"2008","unstructured":"Jansson, M. et al. Arginine methylation regulates the p53 response. Nat. Cell Biol. 10(12), 1431\u20131439. https:\/\/doi.org\/10.1038\/ncb1802 (2008).","journal-title":"Nat. Cell Biol."},{"issue":"15","key":"48652_CR65","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1093\/nar\/gkp516","volume":"37","author":"A Scoumanne","year":"2009","unstructured":"Scoumanne, A., Zhang, J. & Chen, X. PRMT5 is required for cell-cycle progression and p53 tumor suppressor function. Nucleic Acids Res. 37(15), 4965\u20134976. https:\/\/doi.org\/10.1093\/nar\/gkp516 (2009).","journal-title":"Nucleic Acids Res."},{"issue":"28\u201329","key":"48652_CR66","doi-asserted-by":"publisher","first-page":"6603","DOI":"10.1016\/j.febslet.2006.11.008","volume":"580","author":"M Inamitsu","year":"2006","unstructured":"Inamitsu, M., Itoh, S., Hellman, U., ten Dijke, P. & Kato, M. Methylation of Smad6 by protein arginine N -methyltransferase 1. FEBS Lett. 580(28\u201329), 6603\u20136611. https:\/\/doi.org\/10.1016\/j.febslet.2006.11.008 (2006).","journal-title":"FEBS Lett."},{"issue":"1","key":"48652_CR67","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1365-2443.2008.01246.x","volume":"14","author":"T Tabata","year":"2009","unstructured":"Tabata, T., Kokura, K., ten Dijke, P. & Ishii, S. Ski co-repressor complexes maintain the basal repressed state of the TGF-\u03b2 target gene, SMAD7, via HDAC3 and PRMT5. Genes Cells 14(1), 17\u201328. https:\/\/doi.org\/10.1111\/j.1365-2443.2008.01246.x (2009).","journal-title":"Genes Cells"},{"issue":"1","key":"48652_CR68","doi-asserted-by":"publisher","first-page":"9711","DOI":"10.1038\/s41598-018-28002-y","volume":"8","author":"SV Gerhart","year":"2018","unstructured":"Gerhart, S. V. et al. Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing. Sci. Rep. 8(1), 9711. https:\/\/doi.org\/10.1038\/s41598-018-28002-y (2018).","journal-title":"Sci. Rep."},{"issue":"17","key":"48652_CR69","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1101\/gad.219899.113","volume":"27","author":"M Bezzi","year":"2013","unstructured":"Bezzi, M. et al. Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery. Genes Dev. 27(17), 1903\u20131916. https:\/\/doi.org\/10.1101\/gad.219899.113 (2013).","journal-title":"Genes Dev."},{"issue":"2","key":"48652_CR70","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1042\/BJ20120768","volume":"446","author":"Z Gu","year":"2012","unstructured":"Gu, Z. et al. Protein arginine methyltransferase 5 is essential for growth of lung cancer cells. Biochem. J. 446(2), 235\u2013241. https:\/\/doi.org\/10.1042\/BJ20120768 (2012).","journal-title":"Biochem. J."},{"key":"48652_CR71","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1016\/j.celrep.2017.11.096","volume":"21","author":"K Chiang","year":"2017","unstructured":"Chiang, K. et al. PRMT5 is a critical regulator of breast cancer stem cell function via histone methylation and FOXP1 expression. Cell Reports 21, 3498\u20133513. https:\/\/doi.org\/10.1016\/j.celrep.2017.11.096 (2017).","journal-title":"Cell Reports"},{"issue":"6","key":"48652_CR72","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1093\/NAR\/GKAA065","volume":"48","author":"F Liu","year":"2020","unstructured":"Liu, F. et al. PRMT5-mediated histone arginine methylation antagonizes transcriptional repression by polycomb complex PRC2. Nucleic Acids Res 48(6), 2956. https:\/\/doi.org\/10.1093\/NAR\/GKAA065 (2020).","journal-title":"Nucleic Acids Res"},{"key":"48652_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00239","author":"KE Warren","year":"2018","unstructured":"Warren, K. E. \u2018Beyond the blood: Brain barrier: The importance of central nervous system (CNS) pharmacokinetics for the treatment of CNS tumors including diffuse intrinsic pontine glioma. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2018.00239 (2018).","journal-title":"Front. Oncol."},{"issue":"6","key":"48652_CR74","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3390\/molecules23061289","volume":"23","author":"I Zeiadeh","year":"2018","unstructured":"Zeiadeh, I., Najjar, A. & Karaman, R. Strategies for enhancing the permeation of CNS-active drugs through the blood-brain barrier: A review. Molecules 23(6), 1289. https:\/\/doi.org\/10.3390\/molecules23061289 (2018).","journal-title":"Molecules"},{"key":"48652_CR75","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/S0959-8049(22)01021-8","volume":"174","author":"K Briggs","year":"2022","unstructured":"Briggs, K. et al. TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancer. Eur J Cancer 174, S84. https:\/\/doi.org\/10.1016\/S0959-8049(22)01021-8 (2022).","journal-title":"Eur J Cancer"},{"issue":"6","key":"48652_CR76","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis, D. N. et al. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131(6), 803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1 (2016).","journal-title":"Acta Neuropathol."},{"issue":"3","key":"48652_CR77","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1055\/S-0042-105292","volume":"228","author":"M Wiese","year":"2016","unstructured":"Wiese, M. et al. No significant cytotoxic effect of the EZH2 inhibitor tazemetostat (EPZ-6438) on pediatric glioma cells with wildtype histone 3 or mutated histone 3.3. Klin. Padiatr. 228(3), 113\u2013117. https:\/\/doi.org\/10.1055\/S-0042-105292 (2016).","journal-title":"Klin. Padiatr."},{"key":"48652_CR78","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.canlet.2017.04.019","volume":"400","author":"H Miyahara","year":"2017","unstructured":"Miyahara, H. et al. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. Cancer Lett. 400, 110\u2013116. https:\/\/doi.org\/10.1016\/j.canlet.2017.04.019 (2017).","journal-title":"Cancer Lett."},{"issue":"13","key":"48652_CR79","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1158\/1078-0432.CCR-19-3538","volume":"26","author":"MH Meel","year":"2020","unstructured":"Meel, M. H. et al. Combined therapy of AXL and HDAC inhibition reverses mesenchymal transition in diffuse intrinsic pontine glioma. Clin. Cancer Res. 26(13), 3319\u20133332. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3538 (2020).","journal-title":"Clin. Cancer Res."},{"key":"48652_CR80","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1201","author":"DM Carvalho","year":"2021","unstructured":"Carvalho, D. M. et al. Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1201 (2021).","journal-title":"Cancer Discov."},{"issue":"9","key":"48652_CR81","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/neuonc\/noab014","volume":"23","author":"Y Otani","year":"2021","unstructured":"Otani, Y. et al. Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma. Neuro Oncology 23(9), 1481\u20131493. https:\/\/doi.org\/10.1093\/neuonc\/noab014 (2021).","journal-title":"Neuro Oncology"},{"issue":"4","key":"48652_CR82","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/neuonc\/noab188","volume":"24","author":"JM Su","year":"2022","unstructured":"Su, J. M. et al. Phase I\/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children\u2019s Oncology Group report. Neuro Oncology 24(4), 655\u2013664. https:\/\/doi.org\/10.1093\/neuonc\/noab188 (2022).","journal-title":"Neuro Oncology"},{"issue":"4","key":"48652_CR83","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00726-020-02937-x","volume":"53","author":"SF Samuel","year":"2021","unstructured":"Samuel, S. F., Barry, A., Greenman, J. & Beltran-Alvarez, P. Arginine methylation: The promise of a \u201csilver bullet\u201d for brain tumours?. Amino Acids 53(4), 489\u2013506. https:\/\/doi.org\/10.1007\/s00726-020-02937-x (2021).","journal-title":"Amino Acids"},{"issue":"6","key":"48652_CR84","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1158\/0008-5472.CAN-13-0884","volume":"74","author":"F Yan","year":"2014","unstructured":"Yan, F. et al. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Cancer Res. 74(6), 1752\u20131765. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-0884 (2014).","journal-title":"Cancer Res."},{"issue":"3","key":"48652_CR85","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/J.MOLONC.2014.10.015","volume":"9","author":"JH Park","year":"2015","unstructured":"Park, J. H. et al. Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells. Mol. Oncol. 9(3), 617. https:\/\/doi.org\/10.1016\/J.MOLONC.2014.10.015 (2015).","journal-title":"Mol. Oncol."},{"issue":"1","key":"48652_CR86","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1186\/s12885-019-6291-z","volume":"19","author":"NK Chaturvedi","year":"2019","unstructured":"Chaturvedi, N. K. et al. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma. BMC Cancer 19(1), 1056. https:\/\/doi.org\/10.1186\/s12885-019-6291-z (2019).","journal-title":"BMC Cancer"},{"key":"48652_CR87","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317695917","author":"Y Wu","year":"2017","unstructured":"Wu, Y., Wang, Z., Zhang, J. & Ling, R. Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer. Tumour Biol. https:\/\/doi.org\/10.1177\/1010428317695917 (2017).","journal-title":"Tumour Biol."},{"issue":"4","key":"48652_CR88","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/LEU.2017.334","volume":"32","author":"A Gull\u00e0","year":"2018","unstructured":"Gull\u00e0, A. et al. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia 32(4), 996\u20131002. https:\/\/doi.org\/10.1038\/LEU.2017.334 (2018).","journal-title":"Leukemia"},{"issue":"1","key":"48652_CR89","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/NEUONC\/NOU104","volume":"17","author":"MH Jansen","year":"2015","unstructured":"Jansen, M. H. et al. Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro Oncology 17(1), 160\u2013166. https:\/\/doi.org\/10.1093\/NEUONC\/NOU104 (2015).","journal-title":"Neuro Oncology"},{"issue":"2","key":"48652_CR90","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1158\/1541-7786.MCR-20-0464\/81767\/AM\/TRANSCRIPTOMIC-ANALYSIS-OF-DIFFUSE-INTRINSIC","volume":"19","author":"RK Surowiec","year":"2021","unstructured":"Surowiec, R. K. et al. Transcriptomic analysis of diffuse intrinsic pontine glioma (DIPG) identifies a targetable ALDH-positive subset of highly tumorigenic cancer stem-like cells. Mol. Cancer Res. 19(2), 223\u2013239. https:\/\/doi.org\/10.1158\/1541-7786.MCR-20-0464\/81767\/AM\/TRANSCRIPTOMIC-ANALYSIS-OF-DIFFUSE-INTRINSIC (2021).","journal-title":"Mol. Cancer Res."},{"key":"48652_CR91","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/J.GENE.2018.09.052","volume":"681","author":"A Ku\u015fo\u011flu","year":"2019","unstructured":"Ku\u015fo\u011flu, A. & Biray Avc\u0131, \u00c7. \u2018Cancer stem cells: A brief review of the current status. Gene 681, 80\u201385. https:\/\/doi.org\/10.1016\/J.GENE.2018.09.052 (2019).","journal-title":"Gene"},{"issue":"11","key":"48652_CR92","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1073\/pnas.1101657108","volume":"108","author":"M Monje","year":"2011","unstructured":"Monje, M. et al. \u2018Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc. Natl. Acad. Sci. USA 108(11), 4453\u20134458. https:\/\/doi.org\/10.1073\/pnas.1101657108 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"48652_CR93","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/biomet\/93.3.491","volume":"93","author":"Y Benjamini","year":"2006","unstructured":"Benjamini, Y., Krieger, A. M. & Yekutieli, D. Adaptive linear step-up procedures that control the false discovery rate. Biometrika 93(3), 491\u2013507. https:\/\/doi.org\/10.1093\/biomet\/93.3.491 (2006).","journal-title":"Biometrika"},{"issue":"99","key":"48652_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3791\/52686","volume":"2015","author":"M Vinci","year":"2015","unstructured":"Vinci, M., Box, C. & Eccles, S. A. Three-dimensional (3D) tumor spheroid invasion assay. J. Vis. Exp. 2015(99), 1\u20139. https:\/\/doi.org\/10.3791\/52686 (2015).","journal-title":"J. Vis. Exp."},{"issue":"5","key":"48652_CR95","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34(5), 525\u2013527. https:\/\/doi.org\/10.1038\/nbt.3519 (2016).","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"48652_CR96","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B (Methodological) 57(1), 289\u2013300. https:\/\/doi.org\/10.1111\/j.2517-6161.1995.tb02031.x (1995).","journal-title":"J. R. Stat. Soc. Ser. B (Methodological)"},{"issue":"5","key":"48652_CR97","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/OMI.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: An R package for comparing biological themes among gene clusters. Omics 16(5), 284\u2013287. https:\/\/doi.org\/10.1089\/OMI.2011.0118 (2012).","journal-title":"Omics"},{"issue":"1","key":"48652_CR98","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28(1), 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27 (2000).","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"48652_CR99","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51(D1), D587\u2013D592. https:\/\/doi.org\/10.1093\/nar\/gkac963 (2023).","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"48652_CR100","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28(11), 1947\u20131951. https:\/\/doi.org\/10.1002\/pro.3715 (2019).","journal-title":"Protein Sci."},{"issue":"15","key":"48652_CR101","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1093\/BIOINFORMATICS\/BTX180","volume":"33","author":"I Arganda-Carreras","year":"2017","unstructured":"Arganda-Carreras, I. et al. Trainable weka segmentation: A machine learning tool for microscopy pixel classification. Bioinformatics 33(15), 2424\u20132426. https:\/\/doi.org\/10.1093\/BIOINFORMATICS\/BTX180 (2017).","journal-title":"Bioinformatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48652-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48652-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48652-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T11:04:14Z","timestamp":1704279854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48652-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["48652"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-48652-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]},"assertion":[{"value":"5 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"328"}}